{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:48:27Z","timestamp":1775868507103,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Geriatrics Gerontology Int"],"published-print":{"date-parts":[[2024,9]]},"abstract":"\n Aim<\/jats:title>\n To date, there is no reported effective biomarker that can predict which Alzheimer's disease (AD) patients will respond to donepezil and which will not. This study aimed to investigate whether baseline values of A\u03b2 oligomers (A\u03b2Os), measured by the Multimer Detection System\u2010Oligomeric A\u03b2 (MDS\u2010OA\u03b2), can be used to predict responders after 6\u2009months of donepezil medication.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n The study enrolled 104 patients diagnosed with probable AD. After 6\u2009months of donepezil medication, the response to treatment was evaluated by re\u2010assessing the Korean version of the Mini\u2010Mental State Examination (K\u2010MMSE) and Clinical Dementia Rating scale\u2010Sum of Box (CDR\u2010SB) scales conducted at baseline. The patients were categorized into two groups according to the baseline MDS\u2010OA\u03b2 values known as the cut\u2010off for AD diagnosis: a group with values below 0.78 and another group with values equal to or above 0.78.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n After 6\u2009months of medication, the number of responders was 50 (49.5%). Responders exhibited significantly worse baseline CDR, CDR\u2010SB, K\u2010MMSE, and Barthel index compared with non\u2010responders. There was a significantly higher number of responders among patients with MDS\u2010OA\u03b2 values below the cut\u2010off of 0.78 compared with those with values equal to or above this threshold. Furthermore, there was a significant improvement in the K\u2010MMSE and CDR\u2010SB after 6\u2009months of donepezil medication in patients with MDS\u2010OA\u03b2 values below 0.78 compared with those with values equal to or above 0.78.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Baseline MDS\u2010OA\u03b2 values might constitute a novel biochemical marker for the efficacy of 6 months of donepezil treatment in AD.\n Geriatr Gerontol Int 2024; 24: 918\u2013923<\/jats:bold>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/ggi.14958","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T04:25:15Z","timestamp":1723782315000},"page":"918-923","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Relationship between the response to donepezil and plasma amyloid beta oligomers in patients with Alzheimer's disease"],"prefix":"10.1111","volume":"24","author":[{"given":"YoungSoon","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Neurology Soonchunhyang University College of Medicine, Cheonan Hospital Cheonan Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoon","family":"Huh","sequence":"additional","affiliation":[{"name":"Department of Neurology Hyoja Geriatric Hospital Yongin Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4195-8971","authenticated-orcid":false,"given":"Yong Tae","family":"Kwak","sequence":"additional","affiliation":[{"name":"Department of Neurology Hyoja Geriatric Hospital Yongin Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,8,16]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-019-0333-5"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201606210"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt226"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-179941"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00873-w"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2009.05.024"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0310-6"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0324-0"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0499-7"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0946-1"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200421010-00004"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.998224"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200825080-00007"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23933"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.9.1021"},{"key":"e_1_2_9_18_1","first-page":"34","article-title":"Treatment effect of donepezil is greater in moderate stage than in mild stage of AD","volume":"1","author":"Jung MS","year":"2013","journal-title":"J Neurol Res"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1402"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1028448"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/1533317507313675"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.55782\/ane-2007-1640"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.2195"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.321448"}],"container-title":["Geriatrics & Gerontology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ggi.14958","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ggi.14958","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ggi.14958","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T23:49:18Z","timestamp":1775864958000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ggi.14958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1111\/ggi.14958"],"URL":"https:\/\/doi.org\/10.1111\/ggi.14958","archive":["Portico"],"relation":{},"ISSN":["1444-1586","1447-0594"],"issn-type":[{"value":"1444-1586","type":"print"},{"value":"1447-0594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,16]]},"assertion":[{"value":"2024-05-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}